Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

November 30, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Advanced Malignant Solid Tumor
Interventions
BIOLOGICAL

BNT314

Intravenous infusion

Trial Locations (14)

2018

GZA Ziekenhuizen, Antwerp

4000

CHU de Liège, Liège

28040

Hospital Fund. Jiménez Dia, Madrid

28050

Hospital HM Univ. Sanchinarro, Ensayos START, Madrid

28078

Carolina BioOncology Institute, LLC, Huntersville

31008

Clinica Universidad de Navarra, Pamplona

44195

Cleveland Clinic, Cleveland

49546

START Midwest, Grand Rapids

DK-2100

Rigshospitalet, Copenhagen

277-8577

National Cancer Center Hospital East, Kashiwanoha

08023

Hospital Quironsalud Barcelona (NEXT Barcelona), Barcelona

SW36JJ

Royal Marsden Hospital - London, London

M20 4BX

The Christie Hospital, Manchester

NE7 7DN

Northern Centre for Cancer Care, Newcastle

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Genmab

INDUSTRY

lead

BioNTech SE

INDUSTRY